EQS-Adhoc : IGEA announces three new board members

EQS Group-Ad-hoc: IGEA Pharma N.V. / Key word(s): Miscellaneous 
IGEA announces three new board members 
22-March-2021 / 22:09 CET/CEST 
Release of an ad hoc announcement pursuant to Art. 18 KR 
The issuer is solely responsible for the content of this announcement. 
=---------------------------------------------------------------------------------------------------------------------- 
IGEA announces three new board members 
This press release complements today's announcement "IGEA calls extraordinary general meeting" to be viewed on https:// 
www.igeapharma.nl/category/press-releases| 
Hoofddorp, the Netherlands, 22 March 2021. IGEA Pharma N.V. (SIX: IGPH) today announced important changes in its board 
of directors. As announced today by separate press release, new persons were bindingly nominated for election as 
non-executive directors in the board of IGEA at the upcoming extraordinary general meeting of 28 April 2021. 
Coming from various economic environments, the new board members will bring years of experience and leadership to help 
the combined businesses of IGEA and Blue Sky Natural Resources LTD to establish market position for health prevention, 
pharmaceutical, nutraceutical and cosmeceutical solutions based on CBD and other high quality vegetable matrices 
extracts, leverage commercial capabilities and partnerships, and capitalize on the financial leverage and operational 
synergies to improve return on capital and achieve profitability. 
The new persons nominated for election in the general meeting include: 
- Giovanna Puppo, Equity Partner at Grimaldi Studio Legale, Milan; 
- Massimiliano Colella, group CEO at EVERCARE, Dubai; 
- Raffaele Bruto Bertoni, Head of Debt Capital Market and Senior Portfolio Manager at GIC Gulf Investment Corporation, 
Kuwait City. 
The CVs of Giovanna Puppo, Massimiliano Colella and Raffaele Bruto Bertoni are available on https://www.igeapharma.nl/ 
category/information-for-shareholders/. 
*** 
About IGEA 
IGEA Pharma N.V. focuses on health-tech and med-tech products and devices. Health-tech products are exclusively 
preventative. IGEA commercializes an Alzheimer's prevention set (which includes 'Alz1', an at-home lab test kit to 
measure non-bound copper in the blood and a natural dietary supplement branded 'Alz1 Tab' designed to reduce blood 
heavy metals content) and expects to integrate the non-bound copper detection-based pipeline with a diabetes type II 
prevention set in 2021. Non-bound copper is an expected Alzheimer's and diabetes type II associated biomarker. 
Controlling non-bound copper can contribute to reduce the risk of Alzheimer's and diabetes type II. IGEA furthermore 
commercializes a COVID19 rapid test for the detection of IgM and IgG SARS-CoV-2 related antibodies. Med-tech products 
focuses on selected solutions and specialties, among which dry aerosol generators for air and inanimate environmental 
surfaces sanitization and sterilization and air purification devices. 
IGEA is listed on the SIX Swiss Exchange (ticker IGPH) and is headquartered in Hoofddorp, the Netherlands. Find out 
more at www.igeapharma.nl 
Contacts 
Vincenzo Moccia, CEO, [phone], [e-mail] 
Patrick Pozzorini, CFO, [phone], [e-mail] 
Disclaimer 
This document constitutes neither an offer to buy nor to subscribe securities and neither this document nor any part of 
it should form the basis of any investment decision in IGEA. The information contained in this press release has been 
carefully prepared. However, IGEA bears and assumes no liability of whatever kind for the correctness and completeness 
of the information provided herein. IGEA does not assume an obligation of whatever kind to update or correct 
information contained in this press release whether as a result of new information, future events or for other reasons. 
This publication may contain specific forward-looking statements and assessments or intentions concerning IGEA and its 
business. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which 
may result in a substantial divergence between the actual results, financial situation, development or performance of 
IGEA and those explicitly or implicitly presumed in these statements. Against the background of these uncertainties, 
readers should not rely on forward-looking statements. IGEA assumes no responsibility to update forward looking 
statements or to adapt them to future events or developments, except as may be required by law. 
Additional features: 
File: 20210322 igea nv_press release II 
=---------------------------------------------------------------------------------------------------------------------- 
End of ad hoc announcement 
=---------------------------------------------------------------------------------------------------------------------- 
Language:     English 
Company:      IGEA Pharma N.V. 
              Siriusdreef 17 
              2123 WT Hoofddorp 
              Netherlands 
Phone:        [phone] 
E-mail:       [e-mail] 
Internet:     www.igeapharma.nl 
ISIN:         NL0012768675 
Listed:       Regulated Unofficial Market in Frankfurt; BX Berne eXchange; SIX Swiss Exchange 
EQS News ID:  1177392 
 
End of Announcement EQS Group News Service 
=------------ 

1177392 22-March-2021 CET/CEST

(END) Dow Jones Newswires

March 22, 2021 17:13 ET (21:13 GMT)